home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Overcoming Late-Stage Formulations & Manufacturing Challenges with KinetiSol Technology

 
  October 17, 2025  
     
 
Xtalks, Online
2025-11-06


Many drug developers rely on spray-dried dispersions (SDDs) for early-phase development of poorly soluble compounds. While this approach offers speed and regulatory familiarity, it often leads to significant challenges later in the development process. Formulation limitations, high pill burden, inefficient solvent use and scale-up issues can make SDDs impractical for late-stage or commercial manufacturing. Join this webinar to explore how converting SDDs to KinetiSol™ dispersions (KSDs) offers a viable solution and how this strategy can enhance manufacturability, enabling the development of more robust drug products.

Spray drying is widely accepted for clinical entry but frequently falls short during scale-up. The limitations are well-known: poor solids loading, excessive solvent use and inefficient tablet manufacturing. These barriers often prevent programs from progressing beyond Phase II.

KinetiSol is a solvent-free, high-energy fusion process that avoids these scale-up bottlenecks. It expands the formulation design space, enabling the development of higher-performing drug products. In this session, a real-world case study will demonstrate how a low-loading SDD was reformulated into a KSD with six times higher bioavailability and improved tablet properties. Key improvements included the elimination of solvents, simplification of the tablet composition and a significant reduction in pill burden.

Attendees will learn how converting to KinetiSol can boost bioavailability, streamline manufacturing and improve scalability for late-stage drug development.

Register for this webinar to learn how KinetiSol solves formulation and manufacturing challenges for late-stage development.

Keywords: API/Formulation Development, Bioavailability, CDMO/CMO, CMC, Commercial Manufacturing, Drug Delivery, Drug Development, Pharmaceutical Manufacturing, Process Development, spray-drying, Tablet Formulation
 
 
Organized by: Xtalks
Invited Speakers: Dave Miller, PhD, Chief Scientific Officer, AustinPx
 
Deadline for Abstracts: 2025-11-06
 
Registration: Free Registration
E-mail: tristan@xtalks.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.